Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molidustat vs Darbepoetin Alfa in ESA-Naive Non-Dialysis Renal Anemia (MIYABI ND-C)
NCT03350321Phase 3
Key facts
- Status
- Completed
- Start
- Dec 2017
- Primary completion
- May 2019
- Countries
- 1
- Sponsor
- Bayer
- Modality
- Small Molecules
- Drugs
- molidustat
- Conditions
- anemia of chronic kidney disease
01
Overview
Phase 3, randomised, open-label trial of molidustat in anemia of chronic kidney disease, sponsored by Bayer. Started Dec 2017; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Results
Primary endpoints met
04
Registry description
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects with renal anemia who are not treated with Erythropoiesis-Stimulating Agents (ESAs).
Beyond the preview
Go deeper on NCT03350321.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350321.